These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32758593)

  • 1. Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation.
    da Costa NF; Fernandes AI; Pinto JF
    Int J Pharm; 2020 Oct; 588():119716. PubMed ID: 32758593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.
    da Costa NF; Daniels R; Fernandes AI; Pinto JF
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends.
    da Costa NF; Daniels R; Fernandes AI; Pinto JF
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 35893791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Simultaneous Differential Scanning Calorimetry-X-ray Diffraction Study of Olanzapine Crystallization from Amorphous Solid Dispersions.
    Askin S; Gonçalves AD; Zhao M; Williams GR; Gaisford S; Craig DQM
    Mol Pharm; 2020 Nov; 17(11):4364-4374. PubMed ID: 33074007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
    Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
    Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk?
    Veith H; Wiechert F; Luebbert C; Sadowski G
    Eur J Pharm Biopharm; 2021 Jan; 158():323-335. PubMed ID: 33296719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfonic Acid Derivatives in the Production of Stable Co-Amorphous Systems for Solubility Enhancement.
    da Costa NF; Santos IA; Fernandes AI; Pinto JF
    J Pharm Sci; 2022 Dec; 111(12):3327-3339. PubMed ID: 36007560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Insight Into the Impact of Polymers on the Hydrate Conversion of Olanzapine Form I in Aqueous Suspensions.
    Paisana MC; Wahl MA; Pinto JF
    J Pharm Sci; 2017 Jul; 106(7):1786-1794. PubMed ID: 28322942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Development of Quasi-isothermal Calorimetry for the Measurement of Drug-Polymer Miscibility and Crystallization Kinetics: Olanzapine-Loaded PLGA Microparticles.
    Askin S; Zhao M; Gonçalves AD; Gaisford S; Craig DQM
    Mol Pharm; 2018 Aug; 15(8):3332-3342. PubMed ID: 29933697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
    Aucamp M; Milne M; Liebenberg W
    AAPS PharmSciTech; 2016 Oct; 17(5):1100-9. PubMed ID: 26531745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and characterization of multi-component tablets containing co-amorphous salts: Combining multimodal non-linear optical imaging with established analytical methods.
    Ojarinta R; Saarinen J; Strachan CJ; Korhonen O; Laitinen R
    Eur J Pharm Biopharm; 2018 Nov; 132():112-126. PubMed ID: 30248394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.
    Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
    Eur J Pharm Biopharm; 2017 Oct; 119():150-160. PubMed ID: 28602869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
    Luebbert C; Wessner M; Sadowski G
    Mol Pharm; 2018 Feb; 15(2):669-678. PubMed ID: 29309155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
    Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartame as a co-former in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
    Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement.
    Szabó P; Sebe I; Stiedl B; Kállai-Szabó B; Zelkó R
    J Pharm Biomed Anal; 2015 Nov; 115():359-67. PubMed ID: 26280924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.
    Edueng K; Mahlin D; Bergström CAS
    Pharm Res; 2017 Sep; 34(9):1754-1772. PubMed ID: 28523384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the Solubility, Dissolution, and Bioavailability of Ibrutinib by Preparing It in a Coamorphous State With Saccharin.
    Shi X; Song S; Ding Z; Fan B; Huang W; Xu T
    J Pharm Sci; 2019 Sep; 108(9):3020-3028. PubMed ID: 31067482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.